Researcher Profile

Researcher Profile

David Claxton, MD

David Claxton, MD

Professor, Department of Medicine
Division of Hematology and Oncology
Scientific Program:Experimental Therapeutics
Disease Teams:
Bone Marrow Transplantation
Immunotherapy
Leukemia and Lymphoma
dfc10@psu.edu

Research Interests

Dr. David Claxton has longstanding interests in leukemia biology and therapeutics. Leukemia molecular genetics and diagnostics are ongoing interests. Acute myeloid leukemia and related disorders are his principal foci. Leukemia therapeutics are particular interests, including drug development and clinical studies, blood and marrow transplantation, and clinical supportive care. He has a laboratory which has banked many samples of human leukemias and lymphomas. These are viably cryopreserved, used in studies and available to collaborators.

  • Acute Myeloid Leukemia
  • Therapeutics
  • Leukemia
  • Neoplasms
  • Bone Marrow
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Genes
  • Proteins
  • T-Lymphocytes
  • Stem Cells
  • Transplants
  • Drug Therapy

Clinical Trials

MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
MATCH Treatment Subprotocol F: Crizotinib in Patients with Tumors (Other Than Adenocarcinoma of Lung or ALCL) with ALK Rearrangements
MATCH Treatment Subprotocol G: Phase II Study of Crizotinib in Patients with ROS1 Translocations (Other Than Patients with Non-Small Cell Lung Cancer)
MATCH Treatment Subprotocol L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
MATCH Treatment Subprotocol M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations
MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations
MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with c-Kit Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor).
Blood and Bone Marrow Collection from Patients with Hematological Malignancies for Study of Anti-Tumor Immunity
Biologic Studies of Experimental Anti-Cancer Therapeutics in Human Leukemia Cells
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications
T-Cell Exhaustion in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia
Protocol for a Research Sample Repository for Allogeneic Hematopoietic Stem Cell Transplantation
Protocol for a Research Database for Hematopoietic Cell Transplantation, other Cellular Therapies and Marrow Toxic Injuries.

Recent Publications

2019

Stock, W, Luger, SM, Advani, AS, Yin, J, Harvey, RC, Mullighan, CG, Willman, CL, Fulton, N, Laumann, KM, Malnassy, G, Paietta, E, Parker, E, Geyer, S, Mrózek, K, Bloomfield, CD, Sanford, B, Marcucci, G, Liedtke, M, Claxton, D, Foster, MC, Bogart, JA, Grecula, JC, Appelbaum, FR, Erba, H, Litzow, MR, Tallman, MS, Stone, RM & Larson, RA 2019, 'A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: Results of CALGB 10403', Blood, vol. 133, no. 14, pp. 1548-1559. https://doi.org/10.1182/blood-2018-10-881961
Tan, SF, Dunton, W, Liu, X, Fox, TE, Morad, SAF, Desai, D, Doi, K, Conaway, MR, Amin, S, Claxton, D, Wang, HG, Kester, M, Cabot, MC, Feith, DJ & Loughran, TP 2019, 'Acid ceramidase promotes drug resistance in acute myeloid leukemia through NF-κB-dependent P-glycoprotein upregulation', Journal of Lipid Research, vol. 60, no. 6, pp. 1078-1086. https://doi.org/10.1194/jlr.M091876
Kong, Y, Jia, B, Zhao, C, Claxton, D, Sharma, A, Annageldiyev, C, Fotos, J, Zeng, H, Paulson, R, Prabhu, KS & Zheng, H 2019, 'Downregulation of CD73 associates with T cell exhaustion in AML patients' Journal of Hematology and Oncology, vol. 12, no. 1, 40. https://doi.org/10.1186/s13045-019-0728-3
Jia, B, Zhao, C, Rakszawski, KL, Claxton, D, Ehmann, WC, Rybka, W, Mineishi, S, Wang, M, Shike, H, Bayerl, M, Sivik, JM, Schell, T, Drabick, J, Hohl, R & Zheng, H 2019, 'Eomes+T-betlow CD8+ T cells are functionally impaired and are associated with poor clinical outcome in patients with acute myeloid leukemia', Cancer Research, vol. 79, no. 7, pp. 1635-1645. https://doi.org/10.1158/0008-5472.CAN-18-3107
Pu, JJ, Poulose, J, Malysz, J, Zhu, J, Fanburg-Smith, J, Claxton, D & Bayerl, M 2019, 'Impact of ruxolitinib on myelofibrosis patients post allogeneic stem cell transplant—a pilot study', British Journal of Haematology. https://doi.org/10.1111/bjh.15967
Kempin, S, Sun, Z, Kay, NE, Paietta, EM, Mazza, JJ, Ketterling, RP, Frankfurt, O, Claxton, D, Saltzman, JN, Srkalovic, G, Callander, NS, Gross, G & Tallman, MS 2019, 'Pentostatin, Cyclophosphamide, and Rituximab Followed by Alemtuzumab for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Phase 2 Trial of the ECOG-Acrin Cancer Research Group (E2903)', Acta Haematologica. https://doi.org/10.1159/000500164
Spurgeon, SE, Sharma, K, Claxton, D, Ehmann, WC, Pu, J, Shimko, S, Stewart, A, Subbiah, N, Palmbach, G, LeBlanc, F, Latour, E, Chen, YY, Mori, M, Hasanali, Z & Epner, EM 2019, 'Phase 1–2 study of vorinostat (SAHA), cladribine and rituximab (SCR) in relapsed B-cell non-Hodgkin lymphoma and previously untreated mantle cell lymphoma', British Journal of Haematology. https://doi.org/10.1111/bjh.16008
Cioccio, J & Claxton, D 2019, 'Therapy of acute myeloid leukemia: therapeutic targeting of tyrosine kinases', Expert Opinion on Investigational Drugs, vol. 28, no. 4, pp. 337-349. https://doi.org/10.1080/13543784.2019.1584610

2018

Jia, B, Wang, L, Claxton, D, Ehmann, WC, Rybka, W, Mineishi, S, Rizvi, S, Shike, H, Bayerl, M, Schell, T, Hohl, R & Zheng, H 2018, 'Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients', Blood Cancer Journal, vol. 8, no. 3, 34. https://doi.org/10.1038/s41408-018-0069-4
Van De Louw, A, Desai, RJ, Zhu, J & Claxton, D 2018, 'Characteristics of early acute respiratory distress syndrome in newly diagnosed acute myeloid leukemia', Leukemia and Lymphoma, vol. 59, no. 10, pp. 2369-2376. https://doi.org/10.1080/10428194.2018.1435874
Rakszawski, K, Miki, K, Claxton, D, Wagner, H, Shike, H, Mineishi, S & Naik, S 2018, 'Clofarabine followed by haploidentical stem cell transplant using fludarabine, busulfan, and total-body irradiation with post-transplant cyclophosphamide in non-remission AML', International journal of hematology, vol. 108, no. 3, pp. 348-350. https://doi.org/10.1007/s12185-018-2431-5
Kokolus, KM, Haley, JS, Koubek, EJ, Gowda, R, Dinavahi, SS, Sharma, A, Claxton, D, Helm, K, Drabick, J, Robertson, G, Neighbors, J, Hohl, R & Schell, T 2019, 'Schweinfurthin natural products induce regression of murine melanoma and pair with anti-PD-1 therapy to facilitate durable tumor immunity', OncoImmunology, vol. 8, no. 2, e1539614. https://doi.org/10.1080/2162402X.2018.1539614
Prabhu, VV, Talekar, MK, Lulla, AR, Kline, CLB, Zhou, L, Hall, J, Van den Heuvel, APJ, Dicker, DT, Babar, J, Grupp, SA, Garnett, MJ, McDermott, U, Benes, CH, Pu, JJ, Claxton, D, Khan, N, Oster, W, Allen, JE & El-Deiry, WS 2018, 'Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies', Cell Cycle, vol. 17, no. 4, pp. 468-478. https://doi.org/10.1080/15384101.2017.1403689
McGill, CM, Tomco, PL, Ondrasik, RM, Belknap, KC, Dwyer, GK, Quinlan, DJ, Kircher, TA, Andam, CP, Brown, TJ, Claxton, D & Barth, BM 2018, 'Therapeutic effect of Northern Labrador tea extracts for acute myeloid leukemia' Phytotherapy Research, vol. 32, no. 8, pp. 1636-1641. https://doi.org/10.1002/ptr.6091
Mato, AR, Nabhan, C, Thompson, MC, Lamanna, N, Brander, DM, Hill, B, Howlett, C, Skarbnik, A, Cheson, BD, Zent, C, Pu, J, Kiselev, P, Goy, A, Claxton, D, Isaac, K, Kennard, KH, Timlin, C, Landsburg, D, Winter, A, Nasta, SD, Bachow, SH, Schuster, SJ, Dorsey, C, Svoboda, J, Barr, P & Ujjani, CS 2018, 'Toxicities and outcomes of 616 ibrutinib-treated patients in the united states: A real-world analysis', Haematologica, vol. 103, no. 5, pp. 874-879. https://doi.org/10.3324/haematol.2017.182907
Wang, L, Jia, B, Claxton, D, Ehmann, WC, Rybka, W, Mineishi, S, Naik, S, Khawaja, MR, Sivik, J, Han, J, Hohl, R & Zheng, H 2018, 'VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML' OncoImmunology, vol. 7, no. 9, e1469594. https://doi.org/10.1080/2162402X.2018.1469594

2017

Zhu, L, Kong, Y, Zhang, J, Claxton, D, Ehmann, WC, Rybka, W, Palmisiano, ND, Wang, M, Jia, B, Bayerl, M, Schell, T, Hohl, R, Zeng, H & Zheng, H 2017, 'Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia', Journal of Hematology and Oncology, vol. 10, no. 1, 124. https://doi.org/10.1186/s13045-017-0486-z
Salzberg, AC, Harris-Becker, A, Popova, E, Keasey, N, Loughran, TP, Claxton, D & Grigoryev, S 2017, 'Genome-wide mapping of histone H3K9me2 in acute myeloid leukemia reveals large chromosomal domains associated with massive gene silencing and sites of genome instability', PLoS One, vol. 12, no. 3, e0173723. https://doi.org/10.1371/journal.pone.0173723
Schneider, C, Bayerl, M, Boyer, C, Desai, R, Claxton, D & Van De Louw, A 2017, 'Increased CD13 expression in acute myeloid leukemia-associated early acute hypoxic respiratory failure', American Journal of Respiratory and Critical Care Medicine, vol. 196, no. 8, pp. 1077-1080. https://doi.org/10.1164/rccm.201701-0080LE
Mato, AR, Hill, BT, Lamanna, N, Barr, PM, Ujjani, CS, Brander, DM, Howlett, C, Skarbnik, AP, Cheson, BD, Zent, CS, Pu, JJ, Kiselev, P, Foon, K, Lenhart, J, Henick Bachow, S, Winter, AM, Cruz, AL, Claxton, D, Goy, A, Daniel, C, Isaac, K, Kennard, KH, Timlin, C, Fanning, M, Gashonia, L, Yacur, M, Svoboda, J, Schuster, SJ & Nabhan, C 2017, 'Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 28, no. 5, pp. 1050-1056. https://doi.org/10.1093/annonc/mdx031
Abendroth, MD, Bayerl, M, Wilkinson, M, Claxton, D & Specht, C 2017, 'Orbital Epstein-Barr Virus-Positive Polymorphic B-Cell Lymphoproliferative Disorder in an Apparently Immunocompetent Woman', Ocular Oncology and Pathology, vol. 4, no. 1, pp. 61-65. https://doi.org/10.1159/000478747
Teye, EK, Sido, A, Xin, P, Finnberg, NK, Gokare, P, Imamura, Y, Salzberg, AC, Shimko, S, Bayerl, M, Ehmann, WC, Claxton, D, Rybka, W, Drabick, J, Wang, H-G, Abraham, T, El-Deiry, WS, Brodsky, RA, J.Hohl, R & Pu, J 2017, 'PIGN gene expression aberration is associated with genomic instability and leukemic progression in acute myeloid leukemia with myelodysplastic features' Oncotarget, vol. 8, no. 18, pp. 29887-29905. https://doi.org/10.18632/oncotarget.15136
Hengst, J, Dick, TE, Sharma, A, Doi, K, Hegde, S, Tan, SF, Geffert, L, Fox, TE, Sharma, AK, Desai, D, Amin, S, Kester, M, Loughran, TP, Paulson, R, Claxton, D, Wang, H-G & Yun, J 2017, 'SKI-178: A multitargeted inhibitor of sphingosine kinase and microtubule dynamics demonstrating therapeutic efficacy in acute myeloid leukemia models' Cancer Translational Medicine, vol. 3, no. 4, pp. 109-121.
Doshi, UA, Shaw, J, Fox, TE, Claxton, D, Loughran, TP & Kester, M 2017, 'STAT3 mediates C6-ceramide-induced cell death in chronic lymphocytic leukemia', Signal Transduction and Targeted Therapy, vol. 2, e17051. https://doi.org/10.1038/sigtrans.2017.51
Perl, AE, Altman, JK, Cortes, J, Smith, C, Litzow, M, Baer, MR, Claxton, D, Erba, HP, Gill, S, Goldberg, S, Jurcic, JG, Larson, RA, Liu, C, Ritchie, E, Schiller, G, Spira, AI, Strickland, SA, Tibes, R, Ustun, C, Wang, ES, Stuart, R, Röllig, C, Neubauer, A, Martinelli, G, Bahceci, E & Levis, M 2017, 'Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study', The Lancet Oncology, vol. 18, no. 8, pp. 1061-1075. https://doi.org/10.1016/S1470-2045(17)30416-3
Levy, MA & Claxton, D 2017, 'Therapeutic inhibition of BCL-2 and related family members', Expert Opinion on Investigational Drugs, vol. 26, no. 3, pp. 293-301. https://doi.org/10.1080/13543784.2017.1290078

2016

Kirschbaum, MH, Frankel, P, Synold, TW, Zain, J, Claxton, D, Tuscano, J, Newman, EM, Gandara, DR & Lara, PN 2018, 'A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium Study' British Journal of Haematology, vol. 180, no. 3, pp. 445-448. https://doi.org/10.1111/bjh.14333
Tan, SF, Liu, X, Fox, TE, Barth, BM, Sharma, A, Turner, SD, Awwad, A, Dewey, A, Doi, K, Spitzer, B, Shah, MV, Morad, SAF, Desai, D, Amin, S, Zhu, J, Liao, JJ, Yun, J, Kester, M, Claxton, D, Wang, H-G, Cabot, MC, Schuchman, EH, Levine, RL, Feith, DJ & Loughran, TP 2016, 'Acid ceramidase is upregulated in AML and represents a novel therapeutic target', Oncotarget, vol. 7, no. 50, pp. 83208-83222. https://doi.org/10.18632/oncotarget.13079
Liu, Q, Chen, L, Atkinson, JM, Claxton, D & Wang, H-G 2016, 'Atg5-dependent autophagy contributes to the development of acute myeloid leukemia in an MLL-AF9-driven mouse model', Cell Death and Disease, vol. 7, no. 9, e2361. https://doi.org/10.1038/cddis.2016.264
Morad, SAF, Ryan, TE, Neufer, PD, Zeczycki, TN, Davis, TS, MacDougall, MR, Fox, TE, Tan, SF, Feith, DJ, Loughran, TP, Kester, M, Claxton, D, Barth, BM, Deering, TG & Cabot, MC 2016, 'Ceramide-tamoxifen regimen targets bioenergetic elements in acute myelogenous leukemia', Journal of Lipid Research, vol. 57, no. 7, pp. 1231-1242. https://doi.org/10.1194/jlr.M067389
Stefanski, M, Jamis-Dow, CA, Bayerl, M, Desai, RJ, Claxton, D & Van De Louw, A 2016, 'Chest radiographic and CT findings in hyperleukocytic acute myeloid leukemia A retrospective cohort study of 73 patients', Medicine (United States), vol. 95, no. 44, e5285. https://doi.org/10.1097/MD.0000000000005285
Van De Louw, A, Desai, RJ, Schneider, CW & Claxton, D 2016, 'Hypoxemia during extreme hyperleukocytosis: How spurious?', Respiratory Care, vol. 61, no. 1, pp. 8-14. https://doi.org/10.4187/respcare.04196
Van De Louw, A, Schneider, CW, Desai, RJ & Claxton, D 2016, 'Initial respiratory status in hyperleukocytic acute myeloid leukemia: Prognostic significance and effect of leukapheresis' Leukemia and Lymphoma, vol. 57, no. 6, pp. 1319-1326. https://doi.org/10.3109/10428194.2015.1094695
Mato, AR, Nabhan, C, Barr, PM, Ujjani, CS, Hill, BT, Lamanna, N, Skarbnik, AP, Howlett, C, Pu, J, Sehgal, AR, Strelec, LE, Vandegrift, A, Fitzpatrick, DM, Zent, CS, Feldman, T, Goy, A, Claxton, D, Bachow, SH, Kaur, G, Svoboda, J, Nasta, SD, Porter, D, Landsburg, DJ, Schuster, SJ, Cheson, BD, Kiselev, P & Evens, AM 2016, 'Outcomes of CLL patients treated with sequential kinase inhibitor therapy: A real world experience', Blood, vol. 128, no. 18, pp. 2199-2205. https://doi.org/10.1182/blood-2016-05-716977
Kong, Y, Zhu, L, Schell, T, Zhang, J, Claxton, D, Ehmann, WC, Rybka, W, George, M, Zeng, H & Zheng, H 2016, 'T-cell immunoglobulin and ITIM domain (TIGIT) associates with CD8+ T-cell exhaustion and poor clinical outcome in AML patients', Clinical Cancer Research, vol. 22, no. 12, pp. 3057-3066. https://doi.org/10.1158/1078-0432.CCR-15-2626

2015

Kong, Y, Zhang, J, Claxton, D, Ehmann, WC, Rybka, W, Zhu, L, Zeng, H, Schell, T & Zheng, H 2015, ' PD-1 hi TIM-3 + T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation ', Blood Cancer Journal, vol. 5, no. 7, e330. https://doi.org/10.1038/bcj.2015.58
Robuccio, A, Ssentongo, P, Sather, M, Claxton, D & Gilliam, FG 2015, 'Intractable myoclonic seizures in an allogeneic stem cell transplant recipient: A rare case of myoclonic epilepsy' Epilepsy and Behavior Case Reports, vol. 4, pp. 48-51. https://doi.org/10.1016/j.ebcr.2015.06.005
Morad, SAF, Tan, SF, Feith, DJ, Kester, M, Claxton, D, Loughran, TP, Barth, BM, Fox, TE & Cabot, MC 2015, 'Modification of sphingolipid metabolism by tamoxifen and N-desmethyltamoxifen in acute myelogenous leukemia - Impact on enzyme activity and response to cytotoxics', Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids, vol. 1851, no. 7, pp. 919-928. https://doi.org/10.1016/j.bbalip.2015.03.001
Abbi, KKS, Rybka, W, Ehmann, WC & Claxton, D 2015, 'Phase I/II study of clofarabine, etoposide, and mitoxantrone in patients with refractory or relapsed acute leukemia' Clinical Lymphoma, Myeloma and Leukemia, vol. 15, no. 1, pp. 41-46. https://doi.org/10.1016/j.clml.2014.06.005

Clinical Trials Search


Children (age < 18 years)
Adults (age >= 18 years)